Jasper Therapeutics (JSPR) Stock Forecast & Price Target

Compare

1,058 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JSPR Analyst Ratings

Moderate Buy

4 Buy

2 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Jasper

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JSPR Stock 12 Month Forecast

Average Price Target

$10.75

▲(547.59% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Jasper Therapeutics in the last 3 months. The average price target is $10.75 with a high forecast of $20.00 and a low forecast of $4.00. The average price target represents a 547.59% change from the last price of $1.66.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","6":"$6","12":"$12","18":"$18","24":"$24"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6,12,18,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.83,3.227692307692308,4.625384615384616,6.023076923076923,7.420769230769231,8.81846153846154,10.216153846153846,11.613846153846154,13.011538461538462,14.40923076923077,15.806923076923079,17.204615384615387,18.60230769230769,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.83,2.516153846153846,3.2023076923076923,3.8884615384615384,4.5746153846153845,5.260769230769231,5.946923076923077,6.633076923076922,7.319230769230769,8.005384615384616,8.69153846153846,9.377692307692307,10.063846153846153,{"y":10.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.83,1.996923076923077,2.163846153846154,2.330769230769231,2.497692307692308,2.664615384615385,2.831538461538462,2.9984615384615383,3.1653846153846157,3.332307692307692,3.4992307692307696,3.666153846153846,3.833076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.97,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$10.75

Lowest Price Target$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emily Bodnar

H.C. Wainwright

$20

Buy

1104.82%

Upside

Reiterated

01/08/26

Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating

Matt Phipps

William Blair

Hold

―

Reiterated

01/08/26

Maintaining Hold on Jasper: Awaiting Critical BEACON CSU Data to Resolve Clinical and Execution Uncertainty

Rowland Mayor

RBC Capital

Hold

140.96%

Upside

Reiterated

01/08/26

RBC Capital Keeps Their Hold Rating on Jasper Therapeutics (JSPR)

Gavin Clark-Gartner

Evercore ISI

$14→$12

Buy

622.89%

Upside

Reiterated

12/18/25

Evercore ISI Remains a Buy on Jasper Therapeutics (JSPR)

Justin Zelin

BTIG

Buy

321.69%

Upside

Reiterated

12/02/25

Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab's Promising Data and Strategic Plans

Yaron Werber

TD Cowen

Buy

―

Reiterated

11/10/25

Positive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating

Silvan Tuerkcan

Citizens JMP

$12→$6

Buy

261.45%

Upside

Reiterated

09/22/25

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMPJasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

Trung Huynh

UBS

$29→$25

Buy

1406.02%

Upside

Reiterated

08/15/25

Jasper Therapeutics price target lowered to $25 from $29 at UBSJasper Therapeutics price target lowered to $25 from $29 at UBS

Pete Stavropoulos

Cantor Fitzgerald

Hold

―

Downgraded

07/07/25

Jasper Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldJasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Jay Olson

Oppenheimer

$65

Buy

3815.66%

Upside

Reiterated

06/16/25

Oppenheimer Remains a Buy on Jasper Therapeutics (JSPR)

Gregory Renza

Truist Financial

$48→$46

Buy

2671.08%

Upside

Reiterated

05/12/25

Analysts Are Bullish on Top Healthcare Stocks: Karyopharm Therapeutics (KPTI), Jasper Therapeutics (JSPR)

Benjamin Burnett

Wells Fargo

$80

Buy

4719.28%

Upside

Reiterated

03/02/25

Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments

Etzer Darout

Barclays

$63

Buy

3695.18%

Upside

Initiated

02/27/25

Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab's Clinical Progress and Financial Stability

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emily Bodnar

H.C. Wainwright

$20

Buy

1104.82%

Upside

Reiterated

01/08/26

Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating

Matt Phipps

William Blair

Hold

―

Reiterated

01/08/26

Maintaining Hold on Jasper: Awaiting Critical BEACON CSU Data to Resolve Clinical and Execution Uncertainty

Rowland Mayor

RBC Capital

Hold

140.96%

Upside

Reiterated

01/08/26

RBC Capital Keeps Their Hold Rating on Jasper Therapeutics (JSPR)

Gavin Clark-Gartner

Evercore ISI

$14→$12

Buy

622.89%

Upside

Reiterated

12/18/25

Evercore ISI Remains a Buy on Jasper Therapeutics (JSPR)

Justin Zelin

BTIG

Buy

321.69%

Upside

Reiterated

12/02/25

Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab's Promising Data and Strategic Plans

Yaron Werber

TD Cowen

Buy

―

Reiterated

11/10/25

Positive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating

Silvan Tuerkcan

Citizens JMP

$12→$6

Buy

261.45%

Upside

Reiterated

09/22/25

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMPJasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

Trung Huynh

UBS

$29→$25

Buy

1406.02%

Upside

Reiterated

08/15/25

Jasper Therapeutics price target lowered to $25 from $29 at UBSJasper Therapeutics price target lowered to $25 from $29 at UBS

Pete Stavropoulos

Cantor Fitzgerald

Hold

―

Downgraded

07/07/25

Jasper Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldJasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Jay Olson

Oppenheimer

$65

Buy

3815.66%

Upside

Reiterated

06/16/25

Oppenheimer Remains a Buy on Jasper Therapeutics (JSPR)

Gregory Renza

Truist Financial

$48→$46

Buy

2671.08%

Upside

Reiterated

05/12/25

Analysts Are Bullish on Top Healthcare Stocks: Karyopharm Therapeutics (KPTI), Jasper Therapeutics (JSPR)

Benjamin Burnett

Wells Fargo

$80

Buy

4719.28%

Upside

Reiterated

03/02/25

Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments

Etzer Darout

Barclays

$63

Buy

3695.18%

Upside

Initiated

02/27/25

Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab's Clinical Progress and Financial Stability

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jasper Therapeutics

1 Month

xxx

Success Rate

8/15 ratings generated profit

Average Return

-2.02%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of -2.02% per trade.

3 Months

xxx

Success Rate

6/15 ratings generated profit

Average Return

+2.83%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +2.83% per trade.

1 Year

Justin ZelinBTIG

Success Rate

2/13 ratings generated profit

Average Return

-51.18%

reiterated a buy rating last month

Copying Justin Zelin's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -51.18% per trade.

2 Years

xxx

Success Rate

2/13 ratings generated profit

Average Return

-52.16%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 15.38% of your transactions generating a profit, with an average return of -52.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JSPR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JSPR has received 7 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. JSPR average Analyst price target in the past 3 months is 10.75.

Each month's total comprises the sum of three months' worth of ratings.

JSPR Financial Forecast

JSPR Earnings Forecast

Next quarter’s earnings estimate for JSPR is -$0.67 with a range of -$0.99 to -$0.44. The previous quarter’s EPS was -$1.13. JSPR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year JSPR has Performed in-line its overall industry.

No data currently available

JSPR Sales Forecast

Next quarter’s sales forecast for JSPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. JSPR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year JSPR has Performed in-line its overall industry.

JSPR Stock Forecast FAQ

What is JSPR’s average 12-month price target, according to analysts?

Based on analyst ratings, Jasper Therapeutics’s 12-month average price target is 10.75.

What is JSPR’s upside potential, based on the analysts’ average price target?

Jasper Therapeutics has 547.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JSPR a Buy, Sell or Hold?

Jasper Therapeutics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.

What is Jasper Therapeutics’s price target?

The average price target for Jasper Therapeutics is 10.75. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $4.00. The average price target represents 547.59% Increase from the current price of $1.66.

What do analysts say about Jasper Therapeutics?

Jasper Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of JSPR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Jasper Therapeutics (JSPR) Stock Forecast & Price Target

JSPR Analyst Ratings

JSPR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Jasper Therapeutics

JSPR Analyst Recommendation Trends

JSPR Financial Forecast

JSPR Earnings Forecast

JSPR Sales Forecast

JSPR Stock Forecast FAQ

Detailed List of Analyst Forecasts